DDInter112 DDInter899
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
Aprepitant {u} (Compound) palliates {v} (Disease) colon cancer
Aprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Aprepitant {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Aprepitant (Compound) resembles Fosaprepitant (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene)
Aprepitant (Compound) palliates colon cancer (Disease)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Aprepitant (Compound) causes Myocardial infarction (Side Effect)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort